| IFN-K | Placebo | p value | |
|---|---|---|---|
| IFN gene signature reduction | −31.3% | −0.4% | <0.0001 |
| Modified BICLA | 35 (41.2%) | 29 (34.5%) | 0.33 |
| SRI(4) | 57 (67.9%) | 54 (65.1%) | 0.62 |
| SRI(4) with CS≤5 mg/d | 43 (54.4%) | 30 (39%) | 0.07 |
| SRI(4) with CS≤5 mg/d (IFN-K subgroup with neutralizing Abs) | 40 (55.6%) | 30 (39.0%) | 0.04 |
| SRI(4) with CS≤7.5 mg/d | 46 (58.2%) | 33 (42.9%) | 0.07 |
| SRI(4) with CS≤7.5 mg/d (IFN-K subgroup with neutralizing Abs) | 43 (59.7%) | 33 (42.9%) | 0.04 |
| LLDAS | 45 (52.9%) | 25 (29.8%) | 0.002 |
| Mean CS dose * | 5.4 mg/d | 7.1 mg/d | 0.009 |
*The mean daily CS dose was lower in the IFN-K group from w28 onwards.